Home › NCT07283042

Evaluation of Clinical Outcomes and Acceptability of an Anatomical Classification for Placenta Accreta Spectrum

Evaluation of Clinical Outcomes and Acceptability of an Anatomical Classification for Placenta Accreta

Who can join

Ages 18 to 55 · Women

Inclusion Criteria:

* Pregnant people suspected of having PAS based on ultrasound findings or clinical risk factors
* Patients undergoing planned surgical intervention for PAS, including a planned cesarean
* Individuals who provide informed consent to participate in the study
* Patients with at least one prenatal assessment before surgery
* Expected age range: 18-55
* Patient has agreed to conservative management approach as part of standard of care if feasible intraoperatively

Exclusion Criteria:

* Patients who decline participation or withdraw consent
* Those with contraindications to the planned surgical procedure

About the study

This study evaluates the clinical implementation of intra-operative topographic classification system for PAS. In addition to a standard of care risk stratification prenatal ultrasound for patients with a risk of PAS, this study adds an additional intraoperative surgical staging protocol to validate the classification system, improve surgical approach, and significantly clinical outcomes of pregnant people with an a prior risk of PAS. The study will involve pregnant patients with PAS risk factor, include data collection spanning prenatal assessment, intraoperative classification, surgical technique implementation and postoperative analysis. The anticipated study duration is approximately 36-48 months.

What is being tested

• Total Hysterectomy (procedure)
• Modified subtotal hysterectomy (procedure)
• One-Step Conservative Surgery (procedure)

Sponsor: University of California, Los Angeles · Participants: 60 · Started: Dec 1, 2025

Contact the study team

• Dana Levin-Lopez, MPH · Phone: 310-794-8893

Official record on ClinicalTrials.gov — NCT07283042

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.